233 related articles for article (PubMed ID: 20592075)
1. Reduced fitness in cell culture of HIV-1 with nonnucleoside reverse transcriptase inhibitor-resistant mutations correlates with relative levels of reverse transcriptase content and RNase H activity in virions.
Wang J; Bambara RA; Demeter LM; Dykes C
J Virol; 2010 Sep; 84(18):9377-89. PubMed ID: 20592075
[TBL] [Abstract][Full Text] [Related]
2. L74V increases the reverse transcriptase content of HIV-1 virions with non-nucleoside reverse transcriptase drug-resistant mutations L100I+K103N and K101E+G190S, which results in increased fitness.
Wang J; Li D; Bambara RA; Yang H; Dykes C
J Gen Virol; 2013 Jul; 94(Pt 7):1597-1607. PubMed ID: 23535575
[TBL] [Abstract][Full Text] [Related]
3. The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities.
Gerondelis P; Archer RH; Palaniappan C; Reichman RC; Fay PJ; Bambara RA; Demeter LM
J Virol; 1999 Jul; 73(7):5803-13. PubMed ID: 10364332
[TBL] [Abstract][Full Text] [Related]
4. Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture.
Archer RH; Dykes C; Gerondelis P; Lloyd A; Fay P; Reichman RC; Bambara RA; Demeter LM
J Virol; 2000 Sep; 74(18):8390-401. PubMed ID: 10954539
[TBL] [Abstract][Full Text] [Related]
5. The HIV-1 reverse transcriptase mutants G190S and G190A, which confer resistance to non-nucleoside reverse transcriptase inhibitors, demonstrate reductions in RNase H activity and DNA synthesis from tRNA(Lys, 3) that correlate with reductions in replication efficiency.
Wang J; Dykes C; Domaoal RA; Koval CE; Bambara RA; Demeter LM
Virology; 2006 May; 348(2):462-74. PubMed ID: 16504235
[TBL] [Abstract][Full Text] [Related]
6. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
Hu Z; Kuritzkes DR
J Virol; 2014 Aug; 88(16):9268-76. PubMed ID: 24899199
[TBL] [Abstract][Full Text] [Related]
7. Reverse transcriptase backbone can alter the polymerization and RNase activities of non-nucleoside reverse transcriptase mutants K101E+G190S.
Wang J; Li D; Bambara RA; Dykes C
J Gen Virol; 2013 Oct; 94(Pt 10):2297-2308. PubMed ID: 23804564
[TBL] [Abstract][Full Text] [Related]
8. Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants.
Dykes C; Fox K; Lloyd A; Chiulli M; Morse E; Demeter LM
Virology; 2001 Jul; 285(2):193-203. PubMed ID: 11437654
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 reverse transcriptase mutants resistant to nonnucleoside reverse transcriptase inhibitors do not adversely affect DNA synthesis: pre-steady-state and steady-state kinetic studies.
Domaoal RA; Bambara RA; Demeter LM
J Acquir Immune Defic Syndr; 2006 Aug; 42(4):405-11. PubMed ID: 16763521
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic Study of Common Non-Nucleoside Reverse Transcriptase Inhibitor-Resistant Mutations with K103N and Y181C Substitutions.
Lai MT; Munshi V; Lu M; Feng M; Hrin-Solt R; McKenna PM; Hazuda DJ; Miller MD
Viruses; 2016 Sep; 8(10):. PubMed ID: 27669286
[TBL] [Abstract][Full Text] [Related]
11. A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.
Nikolenko GN; Delviks-Frankenberry KA; Pathak VK
J Virol; 2010 May; 84(10):5238-49. PubMed ID: 20219933
[TBL] [Abstract][Full Text] [Related]
12. Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infection.
Wang J; Zhang G; Bambara RA; Li D; Liang H; Wu H; Smith HM; Lowe NR; Demeter LM; Dykes C
J Virol; 2011 Oct; 85(20):10861-73. PubMed ID: 21835788
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.
Soulie C; Santoro MM; Storto A; Abdi B; Charpentier C; Armenia D; Jary A; Forbici F; Bertoli A; Gennari W; Andreoni M; Mussini C; Antinori A; Perno CF; Calvez V; Ceccherini-Silberstein F; Descamps D; Marcelin AG
J Antimicrob Chemother; 2020 Apr; 75(4):1026-1030. PubMed ID: 31976534
[TBL] [Abstract][Full Text] [Related]
14. Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities.
Shaw-Reid CA; Feuston B; Munshi V; Getty K; Krueger J; Hazuda DJ; Parniak MA; Miller MD; Lewis D
Biochemistry; 2005 Feb; 44(5):1595-606. PubMed ID: 15683243
[TBL] [Abstract][Full Text] [Related]
15. Ribonuclease H/DNA Polymerase HIV-1 Reverse Transcriptase Dual Inhibitor: Mechanistic Studies on the Allosteric Mode of Action of Isatin-Based Compound RMNC6.
Corona A; Meleddu R; Esposito F; Distinto S; Bianco G; Masaoka T; Maccioni E; Menéndez-Arias L; Alcaro S; Le Grice SF; Tramontano E
PLoS One; 2016; 11(1):e0147225. PubMed ID: 26800261
[TBL] [Abstract][Full Text] [Related]
16. Effects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors.
Xu HT; Colby-Germinario SP; Oliveira M; Rajotte D; Bethell R; Wainberg MA
Antimicrob Agents Chemother; 2014 Aug; 58(8):4515-26. PubMed ID: 24867966
[TBL] [Abstract][Full Text] [Related]
17. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
[TBL] [Abstract][Full Text] [Related]
18. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and antiviral evaluation of novel heteroarylcarbothioamide derivatives as dual inhibitors of HIV-1 reverse transcriptase-associated RNase H and RDDP functions.
Corona A; Onnis V; Deplano A; Bianco G; Demurtas M; Distinto S; Cheng YC; Alcaro S; Esposito F; Tramontano E
Pathog Dis; 2017 Aug; 75(6):. PubMed ID: 28859311
[TBL] [Abstract][Full Text] [Related]
20. Identification of the critical sites of NNRTI-resistance in reverse transcriptase of HIV-1 CRF_BC strains.
Huang Y; Li Z; Xing H; Jiao Y; Ouyang Y; Liao L; Jiang S; Armstrong R; Shao Y; Ma L
PLoS One; 2014; 9(4):e93804. PubMed ID: 24743727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
